NGNE (Neurogene) Other Current Liabilities: $3.19 Mil (As of Mar. 2026)


NGNE Neurogene Inc NGNE
12 GF Score
Price $35.34
! 4 Warning Signs
View Full Analysis

What is Neurogene Other Current Liabilities?

Neurogene NGNE +4.96% 12 Other Current Liabilities is $3.19 Mil as of Mar. 2026. GuruFocus rates NGNE with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Neurogene's other current liabilities for the quarter that ended in Mar. 2026 was $3.19 Mil.

Neurogene's quarterly other current liabilities increased from Sep. 2025 ($4.20 Mil) to Dec. 2025 ($5.64 Mil) but then declined from Dec. 2025 ($5.64 Mil) to Mar. 2026 ($3.19 Mil).

Neurogene's annual other current liabilities declined from Dec. 2023 ($6.71 Mil) to Dec. 2024 ($4.68 Mil) but then increased from Dec. 2024 ($4.68 Mil) to Dec. 2025 ($5.64 Mil).

Neurogene Other Current Liabilities Related Terms

Neurogene Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Neurogene's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurogene Other Current Liabilities Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
3.28 3.52 6.71 4.68 5.64

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 3.00 4.20 5.64 3.19
NGNE
12GF Score
Neurogene Inc NGNE
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurogene Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $3.19 Mil mean?
Neurogene (NGNE) has a Other Current Liabilities of $3.19 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Neurogene.
Is Neurogene's Other Current Liabilities too high?
Neurogene's current Other Current Liabilities is $3.19 Mil. Overall, Neurogene has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Neurogene's Other Current Liabilities compare to STRO and OCGN?
Neurogene's Other Current Liabilities of $3.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Neurogene. Neurogene's current Other Current Liabilities is $3.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurogene stock overvalued right now?
Neurogene (NGNE) has a current Other Current Liabilities of $3.19 Mil. The current Other Current Liabilities is $3.19 Mil. Neurogene's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Neurogene (NGNE), the current Other Current Liabilities is $3.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurogene Business Description

Other Exchanges UU8:Germany
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
12GF Score

Get the complete analysis for NGNE

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.34
Price